Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
NCT07622706
EGFR Positive Non-small Cell Lung Cancer, NSCLC
View Trial DetailsNCT Number: NCT07388771
This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.
The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?
Interested in participating?
Request Info18 year and older
All sexes
Observational
Tongji hospital, Wuhan, Hubei, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Perioperative
Time frame: One year after the treatment ended
event free survival
Contact information is provided by the study sponsor or research team.
Qian Chu
Other
A Study on Multimodal Data Prediction of Outcome to Neoadjuvant Therapy in NSCLC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07622706
EGFR Positive Non-small Cell Lung Cancer, NSCLC
View Trial DetailsNCT05882513
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hangzhou, China
View Trial DetailsNCT07156604
NSCLC, Neoadjuvant Therapy
Shanghai, China
View Trial DetailsNCT07086326
AK112, Bispecific Antibody
Beijing, Beijing Municipality, China
View Trial Details